• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4663739)   Today's Articles (1182)   Subscriber (51587)
Download
Number Citation Analysis
1
Li J, Fu S, Ye C, Li J. Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy. Leuk Res 2024;148:107638. [PMID: 39721469 DOI: 10.1016/j.leukres.2024.107638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Revised: 11/30/2024] [Accepted: 12/17/2024] [Indexed: 12/28/2024]
2
Iyengar V, Hamlin P, Torka P. SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2024:S2152-2650(24)02405-4. [PMID: 39613700 DOI: 10.1016/j.clml.2024.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2024] [Revised: 10/25/2024] [Accepted: 11/03/2024] [Indexed: 12/01/2024]
3
Solana-Altabella A, Rodríguez-Veiga R, Martínez-Cuadrón D, Montesinos P. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? Ann Hematol 2024:10.1007/s00277-024-05891-w. [PMID: 39150561 DOI: 10.1007/s00277-024-05891-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Accepted: 07/10/2024] [Indexed: 08/17/2024]
4
Khoury MK, Thornton MA, Eagleton MJ, Srivastava SD, Zacharias N, Dua A, Mohapatra A. Assessment of fitness for open repair in patients with infrarenal abdominal aortic aneurysms. J Vasc Surg 2024;80:389-396.e2. [PMID: 38614140 DOI: 10.1016/j.jvs.2024.04.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 04/04/2024] [Accepted: 04/07/2024] [Indexed: 04/15/2024]
5
Dogha MM, Shaker H, Abdelazeez A, Abd-El Latif A, ElAdawy MS. Tamsulosin 0.8 mg daily dose in management of BPH patients with failed tamsulosin 0.4 mg monotherapy and unfit for surgical intervention. World J Urol 2024;42:365. [PMID: 38822877 PMCID: PMC11144140 DOI: 10.1007/s00345-024-05050-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2024] [Accepted: 05/06/2024] [Indexed: 06/03/2024]  Open
6
Tauveron-Jalenques U, Lambert J. [Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy]. Bull Cancer 2024;111:435-436. [PMID: 38582741 DOI: 10.1016/j.bulcan.2024.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Revised: 01/10/2024] [Accepted: 01/13/2024] [Indexed: 04/08/2024]
7
Coccolini F, Cucinotta E, Mingoli A, Zago M, Altieri G, Biloslavo A, Caronna R, Cengeli I, Cicuttin E, Cirocchi R, Cobuccio L, Costa G, Cozza V, Cremonini C, Del Vecchio G, Dinatale G, Fico V, Galatioto C, Kuriara H, Lacavalla D, La Greca A, Larghi A, Mariani D, Mirco P, Occhionorelli S, Parini D, Polistina F, Rimbas M, Sapienza P, Tartaglia D, Tropeano G, Venezia P, Venezia DF, Zaghi C, Chiarugi M. Acute cholecystitis management in high-risk, critically ill, and unfit-for-surgery patients: the Italian Society of Emergency Surgery and Trauma (SICUT) guidelines. Updates Surg 2024;76:331-343. [PMID: 38153659 DOI: 10.1007/s13304-023-01729-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 12/05/2023] [Indexed: 12/29/2023]
8
Wang Y, Xu J, Li P, Xu Y, Xue H, Liu P. Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma: efficient and tolerant. Ann Hematol 2024;103:499-510. [PMID: 37957370 DOI: 10.1007/s00277-023-05498-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 10/06/2023] [Indexed: 11/15/2023]
9
Maurillo L, Spagnoli A, Candoni A, Papayannidis C, Borlenghi E, Lazzarotto D, Fianchi L, Sciumè M, Zannier ME, Buccisano F, Del Principe MI, Mancini V, Breccia M, Fanin R, Todisco E, Lunghi M, Palmieri R, Fracchiolla N, Musto P, Rossi G, Venditti A. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy. Leuk Res 2023;127:107040. [PMID: 36801702 DOI: 10.1016/j.leukres.2023.107040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2022] [Revised: 02/08/2023] [Accepted: 02/10/2023] [Indexed: 02/16/2023]
10
MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT. Leuk Res Rep 2021;16:100267. [PMID: 34540583 PMCID: PMC8436161 DOI: 10.1016/j.lrr.2021.100267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Accepted: 09/03/2021] [Indexed: 11/20/2022]  Open
11
Katayama S, Kobayashi Y, Takamoto A, Edamura K, Sadahira T, Iwata T, Nishimura S, Sako T, Wada K, Araki M, Watanabe M, Watanabe T, Nasu Y. Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma. Urol Oncol 2021;39:731.e25-731.e32. [PMID: 33775531 DOI: 10.1016/j.urolonc.2021.02.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 02/13/2021] [Accepted: 02/15/2021] [Indexed: 11/17/2022]
12
Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer 2020;152:165-173. [PMID: 33421923 DOI: 10.1016/j.lungcan.2020.12.027] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 12/06/2020] [Accepted: 12/19/2020] [Indexed: 01/03/2023]
13
Friedlaender A, Banna GL, Buffoni L, Addeo A. Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. Curr Oncol Rep 2019;21:107. [PMID: 31768759 DOI: 10.1007/s11912-019-0852-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
14
Merli F, Cavallo F, Salvi F, Tucci A, Musuraca G, Nassi L, Merli M, Tani M, Gini G, Ferrari A, Molinari AL, Liberati AM, Conconi A, Matteucci P, Bari A, Scalone R, Ferrero S, Zanni M, Mammi C, Luminari S. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. J Geriatr Oncol 2019;11:37-40. [PMID: 31296461 DOI: 10.1016/j.jgo.2019.06.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 06/05/2019] [Accepted: 06/27/2019] [Indexed: 10/26/2022]
15
Visani G, Ferrara F, Di Raimondo F, Loscocco F, Fuligni F, Paolini S, Zammit V, Spina E, Rocchi M, Visani A, Piccaluga PP, Isidori A. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. Leuk Res 2017;62:77-83. [PMID: 28987821 DOI: 10.1016/j.leukres.2017.09.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Revised: 08/25/2017] [Accepted: 09/25/2017] [Indexed: 11/17/2022]
16
De Marinis F, Bria E, Baas P, Tiseo M, Camerini A, Favaretto AG, Gridelli C. Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel. Clin Lung Cancer 2015;16:399-405. [PMID: 25989953 DOI: 10.1016/j.cllc.2015.04.008] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Revised: 04/19/2015] [Accepted: 04/21/2015] [Indexed: 10/23/2022]
17
Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res 2014;39:296-306. [PMID: 25601157 DOI: 10.1016/j.leukres.2014.12.013] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Revised: 11/02/2014] [Accepted: 12/22/2014] [Indexed: 01/03/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel